Musculoskeletal solutions company Globus Medical has agreed to acquire Nevro for a price of around $250m with an aim to expand treatment options for patients.
This all-cash acquisition, valued at $5.85 per share, was unanimously approved by both companies’ boards.
California-based Nevro is a medical device company providing solutions for chronic pain treatment. The company is currently listed on the New York Stock Exchange (NYSE).
Its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, offers treatment for chronic pain in the trunk and limbs, as well as painful diabetic neuropathy.
In November 2024, Nevro secured CE Mark Certification in Europe for its HFX iQ SCS system.
The company also provides minimally invasive treatments for patients with chronic sacroiliac joint pain, setting the standard for lasting patient outcomes.
Last year, Nevro revealed that it is exploring potential partnerships, mergers, or a possible sale. In January 2025, the company confirmed it was still engaged in ongoing discussions to evaluate strategic options.
Nevro CEO and president Kevin Thornal said: “Through Globus Medical’s capabilities, global infrastructure and other resources, we will be better positioned to achieve our full potential to become a broader and more diversified leader in the pain management space.”
Globus Medical, a developer of orthopaedic and surgical robotic technologies, believes that the acquisition will further solidify its position in the musculoskeletal technology sector.
The company’s offer represents a 27% premium to Nevro’s 90-day volume-weighted average price (VWAP) of $4.61, a 38% premium to the 30-day VWAP of $4.23, and a 17% premium to the latter’s closing market price on 5 February.
Globus Medical also reaffirmed 2025 net sales guidance of $2.66bn to $2.69bn.
Following the Nevro acquisition, it expects net sales of $2.80bn to $2.90bn, with earnings per share ranging from $3.10 to $3.4. The acquisition is expected to be accretive in its second year.
Globus Medical president and CEO Dan Scavilla said: “We believe our size and operational capabilities will accelerate market penetration of Nevro’s technology and bring much needed and clinically superior relief to patients suffering from chronic pain.
“In addition, our scale and operational discipline will allow us to optimise Nevro’s financial performance to drive enhanced profitability and create long-term value moving ahead.”
The transaction is expected to close in late Q2 2025, pending approval from Nevro’s shareholders, regulatory clearance, and other customary conditions.
